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The key role played by IgE during allergic responses is well documented and clinically precedented. Here we describe the characteristics of a high affinity anti-IgE antibody (MEDI4212), currently in preclinical development for moderate/severe allergic asthma.
HuFcεRI transfected RBL or LAD2 cells were incubated with IgE ± MEDI4212. Bound IgE was cross-linked using a commercial anti-IgE and cell activation detected using calcium signalling or β-hexosaminidase release. Effect of MEDI4212 on IgE/CD23 interaction was assessed by incubation of IL-4 stimulated IM9 cells with IgE ± MEDI4212 and bound IgE detected by flow cytometry. Effects on IgE production in human B cells (differentiated with APC + IL-4, ± MEDI4212) was evaluated by flow cytometry. Serum free-IgE was measured using ELISA.
MEDI4212 inhibited the IgE-induced calcium signalling of RBL cells with an IC50 of 0.084nM (95%CI 0.073-0.096, n=11), but did not crosslink IgE bound to the cells. MEDI4212 concentration-dependently inhibited FcεRI induced β-hexosaminidase release from the human mast cell line LAD2 with an IC50 of 0.025nM (95%CI 0.016-0.035, n=4). In addition to blocking the binding of IgE to FcεRI, MEDI4212 prevented the binding of IgE to CD23 on the surface of IM9 cells, and was able to concentration-dependently inhibit B cell IgE production with an IC50 of 8nM (95%CI 6-10, n=3). In line with these data, MEDI4212 was able to effectively deplete free IgE from human sera in vitro.
MEDI4212 is a novel, highly potent human IgG that binds specifically to IgE and inhibits IgE binding to FcεRI and CD23. With its higher potency, MEDI4212 offers potential to expand the current anti-IgE therapy patient group to encompass individuals with high serum IgE.
